Learn About Our Services

POLIVY Access Solutions is your resource for access and reimbursement support after POLIVY is prescribed.

Coverage

Help understanding benefits and coverage, such as benefits investigations and prior authorization resources

Learn More

Reimbursement

Sample coding information and resources for denials and appeals

Learn More

Product Distribution

A list of authorized distributors and specialty pharmacies as well as information on our Spoilage Replacement Program

Learn More

Online Patient Enrollment

Submit POLIVY Access Solutions forms and check the status of your service requests online using My Patient Solutions

Learn More

Our Commitment to Patients

Over the past 20+ years,
Genentech has helped over

million

patients access the Genentech medicines they need.

In 2018, we helped more than

270,000

patients access the Genentech medicines they need.

Communication assistance services

POLIVY Access Solutions employs a multilingual call center staff and offers teletypewriter (TTY) services for callers.
 

Important Safety Information & Indication

Indication Statement

POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least 2 prior therapies.

Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Warnings and Precautions
Peripheral Neuropathy: Monitor patients for peripheral neuropathy and modify or discontinue dose accordingly.
Infusion-Related Reactions: Premedicate with an antihistamine and an antipyretic. Monitor patients closely during infusions. Interrupt or discontinue infusion if reactions occur.
Myelosuppression: Monitor complete blood counts. Manage using dose delays or reductions and growth factor support. Monitor for signs of infection.
Serious and Opportunistic Infections: Closely monitor patients for signs of bacterial, fungal, or viral infections.
Progressive Multifocal Leukoencephalopathy (PML): Monitor patients for new or worsening neurological, cognitive, or behavioral changes suggestive of PML.
Tumor Lysis Syndrome: Closely monitor patients with high tumor burden or rapidly proliferating tumors.
Hepatotoxicity: Monitor liver enzymes and bilirubin.
Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 3 months after the last dose.

The Most Common Adverse Reactions
The most common adverse reactions (≥20%) included neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, nausea, pyrexia, decreased appetite, abdominal pain, and pneumonia.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the full Prescribing Information for additional Important Safety Information.